UNSPSC 51102836: Dexamethasone/tobramycin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51102836 Dexamethasone/tobramycin is a Commodity code that nominally covers ophthalmic pharmaceutical products, but recent state and local solicitations tagged under it show minimal relevance to the code's stated scope. The most recent opportunities posted under this code involve naloxone procurement for emergency response, generic pharmaceutical manufacturing and distribution through wholesaler networks, medical and first aid supplies for emergency services, and direct-to-manufacturer prescription program planning — none of which center on dexamethasone/tobramycin eye preparations or ophthalmic medications. The coding mismatch suggests either tagging errors in the source systems or a substantial divergence between the code's nominal definition and actual procurement practice at the jurisdictions surveyed.

The issuing bodies include a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), a municipal fire department (City of Tampa), and a multi-state cooperative purchasing alliance (Minnesota MMCAP). Geographic activity spans Florida, Texas, Minnesota, and Oregon through the MMCAP vehicle. Representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline; the City of Tampa's IFB for medical and first aid supplies (estimated at $700,000) with a March 13, 2026 response date and a sheltered-market set-aside for certified Small Local Business Enterprises; the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026; and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs with an April 3, 2026 response deadline. The code shows little actionable activity aligned to its dexamethasone/tobramycin definition and warrants reclassification review at the source.